Mario Lacerna, MD
Radiation Oncology · Alpena, MINPI 1326130725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $721 and has fallen 57.4% since, to $307 in 2025.
Across 27 payments — averaging $115.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$375
- Johnson & Johnson$375
- Siemens Medical Solutions USA, Inc.$346
- Seagen Inc.$250
- Sanofi$250
- Reflexion Medical, Inc.$156
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,114100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 3 | $375 |
| Johnson & Johnson | 3 | $375 |
| Siemens Medical Solutions USA, Inc. | 2 | $346 |
| Seagen Inc. | 2 | $250 |
| Sanofi | 2 | $250 |
| Reflexion Medical, Inc. | 1 | $156 |
| Blueprint Medicines Corporation | 1 | $135 |
| Genentech USA, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Epizyme, Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $125 |
| Amgen | 1 | $125 |
| Pfizer | 1 | $125 |
| Eisai Inc. | 1 | $125 |
| Tempus AI, Inc | 1 | $107 |
| EMD Serono, Inc. | 1 | $96 |
| AstraZeneca | 1 | $71 |
| Merz North America, Inc. | 1 | $40 |
| Progenics Pharmaceuticals, Inc. | 1 | $26 |
| Icad, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,114 in reported general payments places this provider in the 85th percentile of 198 radiation oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 86 | $1,492 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 39 | $511 |
| SsdSilver Sulfadiazine | 25 | $474 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $266 |
| Oxycodone Hcl | 13 | $248 |
| Lidocaine Hcl ViscousLidocaine Hcl | 22 | $160 |
| Pentoxifylline | 11 | $156 |
| Triamcinolone Acetonide | 23 | $72 |
| Dexamethasone | 18 | $61 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Alpena
- Frank ViciniPontiac$231K
- Thomas BoikeClarkston$171K
- Farzan SiddiquiDetroit$72K
- Daniel WahlAnn Arbor$42K
- Daniel ChangAnn Arbor$38K
- Shruti JollyAnn Arbor$30K
- Brandon ManciniGrand Rapids$30K
- Alvaro MartinezFarmington Hills$24K
- James KaneAnn Arbor$19K
- M Salim SiddiquiDetroit$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.